Josh Saef

Dr. Josh Saef

orcid

Research Focus & Metrics

Academic Career Length

9Years (2018-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
1 August 2020 in EBioMedicine
Verified
Journal Article
Open access
MCMina K. Chung
Mina K. Chung
SKSadashiva Karnik
Sadashiva Karnik
JSJoshua Saef
Joshua Saef
CBCornelia Bergmann
Cornelia Bergmann
JBJohn Barnard
John Barnard
LSLars G. Svensson
Lars G. Svensson
SARS-CoV-2 enters cells by binding of its spike protein to angiotensin-converting enzyme 2 (ACE2). Angiotensin-converting enzyme inhibitors (ACEIs) or angiotensin II receptor blockers (ARBs) have been reported to increase ACE2 expression in animal models, and worse outcomes are reported in patients with co-morbidities commonly treated with these agents, leading to controversy during the COVID-19 pandemic over whether these drugs might be helpful or harmful. : Animal, in vitro and clinical data relevant to the biology of the renin-angiotensin system (RAS), its interaction with the kallikrein-kinin system (KKS) and SARS-CoV-2, and clinical studies were reviewed. SARS-CoV-2 hijacks ACE2to invade and damage cells, downregulating ACE2, reducing its protective effects and exacerbating injurious Ang II effects. However, retrospective observational studies do not show higher risk of infection with ACEI or ARB use. Nevertheless, study of the RAS and KKS in the setting of coronaviral infection may yield therapeutic targets.

Verified
Journal Article
Open access
PDF file
JSJoshua Saef
Joshua Saef
RMRobert Montgomery
Robert Montgomery
ACAri Cedars
Ari Cedars
WTW.H. Wilson Tang
W.H. Wilson Tang
JRJoseph W. Rossano
Joseph W. Rossano
SVSumeet S. Vaikunth
Sumeet S. Vaikunth
Adults with congenital heart disease (ACHD) patients are one of the fastest growing populations in cardiology, and heart failure (HF) is the most common cause of morbidity and mortality amongst them. The need for advanced HF therapies in ACHD patients stands to grow substantially. The anatomic considerations for placing durable mechanical circulatory support (MCS) devices in ACHD patients often require specialized approaches. Despite this, increasing evidence suggests that durable MCS can be implanted safely with favorable outcomes in ACHD patients. Expansion of MCS use in ACHD patients is imperative to improve their clinical outcomes. Knowledge of ACHD-specific anatomic and physiologic considerations is crucial to HF programs’ success as they work to provide care to this growing population.

1 June 2019 in The American Journal of Cardiology
Verified
Journal Article
Closed access
GHGeoffrey D. Huntley
Geoffrey D. Huntley
KTKristen M. Tecson
Kristen M. Tecson
SSSandeep Sodhi
Sandeep Sodhi
JSJoshua Saef
Joshua Saef
KWKamila S. White
Kamila S. White
JKJong Mi Ko
Jong Mi Ko

23 November 2023 in Journal of Clinical Medicine
Verified
Journal Article
Open access
PDF file
JSJoshua Saef
Joshua Saef
MMMichael Trejeeve Martyn
Michael Trejeeve Martyn
ADAnusha Ray Dey
Anusha Ray Dey
RKRola Khedraki
Rola Khedraki
LILauren Ives
Lauren Ives
WTW.H. Wilson Tang
W.H. Wilson Tang
Background: Transthyretin cardiac amyloidosis (ATTR-CM) is classically thought of as a progressive disease with preserved systolic function. The longitudinal clinical trajectories of ATTR-CM with impaired left ventricular ejection fraction (LVEF) remain unclear. Methods: This is a single-center retrospective cohort study of consecutive patients with ATTR-CM who underwent two or more echocardiograms with baseline LVEF < 50%. Patients were stratified according to the presence of ≥5% change in LVEF. A Cox proportional hazard model examined hazard of a composite outcome of death, transplant, or LVAD insertion over the two years following diagnosis. Results: In our study cohort of 179 patients, 62 patients (34.6%) experienced an increase in LVEF while 33 (18.4%) experienced a decrease in LVEF. After adjusting for covariates, patients with a decrease in EF experienced increased hazard of death (HR 2.15, 95% CI 1.05–4.40, p = 0.038) compared to those with stable or an increase in LVEF. Changes in LVEF corresponded with significant differences in NT proBNP trajectories, but initial biomarker levels or clinical staging were not predictive of LVEF trajectory. Conclusions: in ATTR-CM patients with impaired LVEF, over a third demonstrated improved LVEF over time, while those with a decrease in LVEF had worse long-term outcomes.

1 April 2023 in Circulation: Heart Failure
Verified
Journal Article
Closed access
JSJoshua Saef
Joshua Saef
MMMichael Trejeeve Martyn
Michael Trejeeve Martyn
LILauren Ives
Lauren Ives
LRLori R. Roth
Lori R. Roth
JGJustin L. Grodin
Justin L. Grodin
WTW.H. Wilson Tang
W.H. Wilson Tang
Background: Transthyretin amyloid cardiomyopathy (ATTR-CM) is a morbid condition, though recent advances in diagnosis and therapy stand to change its natural history. Patients’ TTR genotype may guide family screening as more treatments and preventive strategies become available. An efficient, intuitive means of determining pretest genetic risk may better inform patients/clinicians when pursuing genetic testing. Methods: This is a cohort study of 767 consecutive patients diagnosed with ATTR-CM who underwent genetic testing. Classification and regression trees (CART) analysis created a decision tree assessing likelihood of carrying a pathologic TTR gene variant. Age, sex, and race were used as independent variables. Logistic regression was also performed to model probability of pathologic TTR genotype. The primary outcome was the decision tree’s accuracy in 2 separate institutions’ ATTR-CM registry. Results: In our study cohort, 208 patients (27.1%) had ATTRv. Race has served most efficiently as the root node followed by age and sex in a CART algorithm, and showed 88.2% accuracy (75.3% sensitivity, 93.9% specificity) in the validation cohort. The odds of having a TTR gene variant were greater in Black patients compared with non-Black patients (OR, 34.6 [95% CI, 20.5–58.3]; P <0.001). Non-Black patients with ATTR-CM aged 69 years and older had <4% risk of having a predisposing mutation. Conclusions: This CART algorithm incorporating age, sex, and race was able to determine which patients with ATTR-CM have pathogenic TTR mutations with high specificity. Non-Black patients diagnosed at age 69 years or older with ATTR-CM have a low likelihood to have ATTRv.

16 August 2023 in Current Heart Failure Reports
Verified
Journal Article
Closed access
PDF file
SVSumeet S. Vaikunth
Sumeet S. Vaikunth
SSSwethika Sundaravel
Swethika Sundaravel
JSJoshua Saef
Joshua Saef
OJOrtega-legaspi Juan
Ortega-legaspi Juan